Trusted Resources: News & Meetings
Latest announcements and gatherings
New Data from Teprotumumab Phase 3 OPTIC Study Shows Significantly Reduced Double Vision and Improved Quality of Life for People With Active Thyroid Eye Disease
Horizon Therapeutics plc today announced new data from the Phase 3 OPTIC confirmatory clinical trial showing that teprotumumab provided significant benefit on several devastating effects of active thyroid eye disease (TED) compared with placebo, including diplopia (double vision), quality of life (QoL) and clinical activity score (CAS). These data were presented during the American Society of Ophthalmic Plastic and Reconstructive Surgery (ASOPRS) 50th Anniversary 2019 Fall Scientific Symposium, and build upon data presented earlier this year that demonstrated the significant benefit of teprotumumab on proptosis (bulging eyes).
Teprotumumab is an investigational medicine for the treatment of active TED and is currently under review by the U.S. Food and Drug Administration (FDA). The teprotumumab Biologics License Application (BLA) was recently granted Priority Review by the FDA and if approved, teprotumumab would be the first FDA-approved medicine for the treatment of active TED. The Prescription Drug User Fee Act (PDUFA) goal date is March 8, 2020.
myBinderRelated Content
-
The Medical University of South Carolina Health Graves’ Eye Disease ClinicThe Medical University of South Carolina...
-
Teprotumumab for Treatment of Thyroid Eye Disease Meets Endpoints in Phase 3 StudyResults from the phase 3 OPTIC study sho...
-
Swaraj Bose, MDDr. Swaraj Bose was an Associate Profess...
-
Sandy Zhang-Nunes, MDSandy Zhang-Nunes, MD, earned her underg...
-
Measuring Health-Related Quality of Life in Thyroid Eye DiseaseHealth-related quality of life (HQOL) is...
-
Diagnosis and Management of Graves Disease – David Cooper, MDEdward H. Livingston, MD discusses Grave...
-
Age and Dose Are Major Risk Factors for Liver Damage Associated with Intravenous Glucocorticoid Pulse Therapy for Gr...Background: High-dose intravenous gluco...
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More Information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.
Powered by
Google